Drug Profile

LYL 331

Alternative Names: LYL-331

Latest Information Update: 17 Oct 2022

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Lyell Immunopharma
Class Antineoplastics; Gene therapies; Immunotherapies; T lymphocyte cell therapies
Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No
Available For Licensing Yes

Highest Development Phases

Preclinical Solid tumours; Synovial sarcoma

Most Recent Events

17 Oct 2022 Preclinical trials in Synovial sarcoma in USA (Parenteral) (Lyell Immunopharma pipeline, October 2022)
29 Mar 2022 Lyell Immunopharma plans to file IND application for LYL 331 in Solid tumours in late 2022 or early 2023
01 Mar 2022 LYL 331 is available for licensing as of 01 Mar 2022. https://lyell.com/story (Lyell Immunopharma pipeline, March 2022)

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com